301 related articles for article (PubMed ID: 33891693)
1. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
[TBL] [Abstract][Full Text] [Related]
2. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.
Cao YX; Jin JL; Sun D; Liu HH; Guo YL; Wu NQ; Xu RX; Zhu CG; Dong Q; Sun J; Li JJ
J Transl Med; 2019 Nov; 17(1):367. PubMed ID: 31711505
[TBL] [Abstract][Full Text] [Related]
3. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Macchi C; Ferri N; Favero C; Cantone L; Vigna L; Pesatori AC; Lupo MG; Sirtori CR; Corsini A; Bollati V; Ruscica M
Eur J Prev Cardiol; 2019 Apr; 26(6):578-588. PubMed ID: 30477320
[TBL] [Abstract][Full Text] [Related]
4. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
Pokharel Y; Virani SS; Ballantyne CM
Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778
[TBL] [Abstract][Full Text] [Related]
5. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
Miname MH; Bittencourt MS; Nasir K; Santos RD
Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
[TBL] [Abstract][Full Text] [Related]
6. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
8. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
[TBL] [Abstract][Full Text] [Related]
9. Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.
Kunimura A; Miura K; Segawa H; Torii S; Kondo K; Hisamatsu T; Kadota A; Fujiyoshi A; Yano Y; Nakagawa Y; Okamura T; Ueshima H
J Atheroscler Thromb; 2023 Jul; 30(7):767-777. PubMed ID: 36123046
[TBL] [Abstract][Full Text] [Related]
10. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
[TBL] [Abstract][Full Text] [Related]
11. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention.
Ali A; Costanzo P; Hoye A
Curr Pharm Des; 2018; 24(4):442-450. PubMed ID: 29332570
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
14. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
[TBL] [Abstract][Full Text] [Related]
15. Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography.
Lee WJ; Chuang HN; Chen YM; Liang KW; Tung H; Chen JP; Lee IT; Wang JS; Lin CH; Lin HJ; Sheu WH; Lee WL; Hsiao TH
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573395
[TBL] [Abstract][Full Text] [Related]
16. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
17. Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.
Gao J; Wang HB; Xiao JY; Ren M; Reilly KH; Li YM; Liu Y
BMJ Open; 2018 Jul; 8(7):e021951. PubMed ID: 29991632
[TBL] [Abstract][Full Text] [Related]
18. A case of heterozygous familial hypercholesterolemia requiring strict low-density lipoprotein cholesterol management with proprotein convertase subtilisin/kexin 9 inhibitor after coronary artery bypass grafting.
Abe T; Sato K; Sekiguchi H; Nakao M; Im J; Sakai A; Yamamoto T; Shoda M; Hagiwara N
J Cardiol Cases; 2021 Sep; 24(3):126-130. PubMed ID: 34466176
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Davis LE; Pogge EK
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
[TBL] [Abstract][Full Text] [Related]
20. Homozygous familial hypercholesterolemia in a young woman with dual gene mutations of low-density lipoprotein receptor and proprotein convertase subtilisin/kexin type 9.
Suppressa P; Carbonara C; Scialpi N; Ciavarella A; Sabbà C
J Clin Lipidol; 2020; 14(2):192-196. PubMed ID: 32088152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
